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Abstract
Epigenetic regulation of gene expression is commonly altered in human cancer. We have observed alterations of DNA
methylation and microRNA expression that reflect the biology of bladder cancer. This common disease arises by distinct
pathways with low and high-grade differentiation. We hypothesized that epigenetic gene regulation reflects an interaction
between histone and DNA modifications, and differences between normal and malignant urothelial cells represent
carcinogenic events within bladder cancer. To test this we profiled two repressive histone modifications (H3K9m3 and
H3K27m3) using ChIP-Seq, cytosine methylation using MeDIP and mRNA expression in normal and malignant urothelial cell
lines. In genes with low expression we identified H3K27m3 and DNA methylation each in 20–30% of genes and both marks
in 5% of genes. H3K9m3 was detected in 5–10% of genes but was not associated with overall expression. DNA methylation
was more closely related to gene expression in malignant than normal cells. H3K27m3 was the epigenetic mark most
specifically correlated to gene silencing. Our data suggest that urothelial carcinogenesis is accompanied by a loss of control
of both DNA methylation and H3k27 methylation. From our observations we identified a panel of genes with cancer
specific-epigenetic mediated aberrant expression including those with reported carcinogenic functions and members
potentially mediating a positive epigenetic feedback loop. Pathway enrichment analysis revealed genes marked by H3K9m3
were involved with cell homeostasis, those marked by H3K27m3 mediated pro-carcinogenic processes and those marked
with cytosine methylation were mixed in function. In 150 normal and malignant urothelial samples, our gene panel correctly
estimated expression in 65% of its members. Hierarchical clustering revealed that this gene panel stratified samples
according to the presence and phenotype of bladder cancer.
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Introduction
Bladder cancer is the fifth commonest malignancy in the United
States with 70, 530 new cases and 14,680 deaths in 2010 [1]. The
majority of tumors are Urothelial Cell Carcinoma (UCC).
Clinicopathological data suggest this disease arises by two distinct
pathways with low and high-grade cellular differentiation. The
clinical phenotype and treatment of these two pathways differs
considerably and molecular comparisons reveal few common events.
The majority of UCC are low-grade tumors, which are character-
ized by FGFR3 mutation, chromosome 9 loss and relatively few
other molecular alterations [2]. In contrast, high-grade tumors have
widespread chromosomal instability, numerous molecular changes
and are best characterized by loss of p53 function.
Molecular changes in cancer arise from either genetic or
epigenetic events. The latter is defined as stable heritable changes
in a chromosome without alterations in the DNA sequence [3].
Epigenetic gene modulation occurs when a stimulus, termed
epigenator, induces a change in gene expression (e.g. by altered
transcription or non-coding RNA) that becomes maintained within
the genome through cell replication and in terminally differentiated
cells [3] [4,5]. Epigenetic maintainers induce an altered chromatin
state by biochemical modification of DNA or histone proteins.
Numerous histone modifications are described and these can be
classified according location, biochemistry or associated gene
expression. Of those that are repressive in nature, trimethylation
(m3) of Histone 3 Lysine 9 (H3K9) and Histone 3 Lysine 27
(H3K27) are some of the best characterized [6,7]. These epigenetic
marks may occur independently or in combination with other
modifications such as H3 lysine 4 methylation, H3K9 mono-
methylation and H2A.Z [8]. At the nucleotide level DNA
methylation mostly occurs at cytosine residues within CpG
dinucleotides. These are concentrated into dense islands typically
around the 59 end of genes. Most human genes contain a CpG
island and the majority of these are unmethylated to allow
associated gene transcription [9]. Cytosine methylation may occur
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physiologically during development or aberrantly in carcinogenesis.
Consequent tumor suppressor gene silencing or oncogene activation
induces and promotes tumorogenesis. Whilst evidence suggests that
epigenetic modifications of DNA and histone interact to modulate
gene expression, the precise sequence and extent of this interaction
is unclear and contrasting reports exist (reviewed in [10]).
We have previously observed changes in DNA methylation and
microRNA expression that reflect the molecular biology of UCC
and are associated with the clinical phenotype of tumors [5,11,12].
In particular, DNA methylation appears a common carcinogenic
event that occurs early in the disease pathway [13] and an
independent predictor of tumor progression [14]. Whilst indicating
an important role for epigenetic gene regulation in UCC, these
studies were limited to only one mechanistic tier of control and did
not analyze histone alterations. To gain a more in depth knowledge
of repressive epigenetic gene regulation in UCC, we have now
profiled H3K9m3 and H3K27m3 in normal and malignant
urothelial cells. We matched these profiles to those for 5-
methylcytosine and gene expression. We hypothesized that
differences represent pro-carcinogenic events within the urothelium.
Results
Histone enrichment in urothelial cells
We performed massively parallel sequencing to determine the
distribution of DNA adjacent to H3K9m3 and H3K27m3 in
urothelial cells. Each experiment yielded between 7.7 M and
18.9 M reads (table S1, mean=13.7 M s.d. = 4.4 M), of which 66–
81% were mapped to unique genomic locations. Whilst reads were
located throughout the entire genome, we observed enrichment
around Transcription Start Sites (TSS, figure 1). The nature of TSS
enrichment varied with histone modification [7]. For example,
H3K9m3 enrichment was more specific to TSS than H3K27m3.
When individual TSS were compared (n= 47,746, Figure S1a), few
shared enrichment in all three cells (n= 151 for H3K9m3 and
n=277 for H3K27m3). When TSS with surrounding CpG islands
were analyzed (n= 28,690), we observed a greater specificity for
H3K9m3 (89–95% of TSS with enrichment had a CpG island) than
for H3K27m3 (28–69%, T Test p,0.001, Figure S1b).
Recent data suggest that many tissue and cancer-specific
differentially DNA methylated regions (T and C-DMRs) occur
within 2 kb around CpG islands (termed CpG island shores [15]).
To examine the relationship between these DMRs and repressive
histone modifications, we calculated enrichment within a 10 kb
window around TSS according to the distance from the nearest C-
DMR (n= 2,708) or T-DMR (n= 16,380) (figure 2). We observed
a different relationship for each of the two classes of DMR. For C-
DMRs, an inverse linear relationship between distance and
enrichment fold was present for both histone modifications. This
relationship was stronger for H3K9m3 and in cancer cell lines,
when compared to H3K27m3 and NHU cells (Pearson coefficients
r =20.90 to20.98 versus20.77 to20.83). Thus, TSS close to C-
DMRs have higher enrichment for repressive histone modifica-
tions, than distant transcription sites. These data support our
observation that H3K9m3 is more specific to TSS with CpG
islands, than H3K27m3. The relationship between T-DMRs and
histone modification was less clear. For H3K9m3 there appeared a
Gaussian distribution with maximal read enrichment at 104 bases
distant. For H3K27m3, the relationship was bimodal with peak
enrichment occurring at both 104 and 107 base distances.
Histone enrichment and mRNA expression
To compare histone modifications with gene expression, we
combined our sequencing data with mRNA expression. Due to
differences in enrichment profiles, used sequencing reads from a
5 kb window around the TSS for H3K9m3 and from the entire
gene for H3K27m3. Matching data were available for 9,998
genes. H3K27m3 was mostly associated with gene silencing. In
total, 85–92% of expressed genes did not have H3K27m3
enrichment (figure 3a) and quantified gene expression appeared
inversely correlated with enrichment (r =20.93 to 20.97,
p,0.0001, figure 3b). TSS with H3K27m3 enrichment had a
less than 10 fold expression than those without this mark (ANOVA
p,0.0001, Figure S2). In contrast, mRNA expression was often
seen with H3K9m3 enrichment (48–56% of enriched genes had
mRNA expression). Indeed, enrichment and mRNA expression
appeared positively correlated when quantified (r = 0.64 to 0.9,
p,0.0001, figure 3b).
DNA methylation, mRNA expression and histone
enrichment
Using MeDIP and CpG island microarrays we identified DNA
regions with and without 5 mC enrichment. We selected the 20%
most enriched probes (defined as DNA hypermethylation), filtered
for those with differences between the malignant and normal cells
(n = 86,414) and selected probes with differential hypermethyla-
tion in the cancerous lines (n = 68,292 (79%)). We mapped these
probes to their nearest neighbors to identify regions with adjacent
(those ,200 bp apart) enriched probes. Depending upon
stringency, we found between 1,513 (5/5 adjacent probes) and
106 (11/11 adjacent probes) CpG islands around 711 and 40
protein-coding genes, respectively. Of these, 20% and 26% were
located within a promoter and the remainder within (66% and
8%) or downstream from the nearest gene. We annotated the
5 mC profile in each cell line for these 68,292 probes using mRNA
expression and obtained data for 10,568 genes (corresponding to
9,799 CpG islands). When measured an inverse correlation was
seen between mRNA expression and 5 mC enrichment for these
probes (r =20.7 to 20.9, p,0.001, figure 4). Reduced gene
expression appeared proportional to the extent of 5 mC
enrichment. We combined the 5 mC and histone enrichments
data to obtain matching patterns for 6,809 genes (figure 4b).
Between 23 and 38% of genes had both epigenetic modifications.
In contrast to mRNA expression, there appeared no differences
between H3K9m3 and H3K27m3 with respect to cell lines or
5 mC enrichment.
Multilayered epigenetic repression of gene expression
To profile epigenetic events in gene repression, we combined
histone enrichment, DNA hypermethylation and gene expression
datasets (matching data for 6,809 genes). In general, DNA and
histone enrichment were negatively correlated to mRNA expres-
sion (figure 5). This relationship appeared most specific for
H3K27m3, as many genes with high expression had enrichment
for H3K9m3. For example, at low mRNA expression levels in EJ
26–28% of genes were enriched for H3K27m3, 11–17% had
associated DNA hypermethylation and 4–6% shared both traits.
The proportion of genes with these epigenetic marks reduced to
less than 5% as mRNA expression increased. The inverse
relationship between H3K9m3 and gene expression was less
strong and direct than for H3K27m3. At low mRNA expression,
11–16% of genes were enriched for H3K9m3, 16–21% had
associated DNA hypermethylation and 2–3% shared both traits.
Of interest, the pattern of enrichment for epigenetic marks did not
vary between malignant and normal cell lines.
To determine specific loci important for urothelial carcinogen-
esis we identified those with cancer-specific silencing and
associated epigenetic modifications. Specifically, we selected genes
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with one or more repressive epigenetic mark (defined as within the
highest 20% of enrichment) that was shared in the two cancer lines
and absent in NHU. From these, we chose genes with reduced
expression in EJ and/or RT112, and preserved expression in
NHU. This strategy identified 239 and 317 genes in EJ and
RT112, respectively (Figure S3a). Of these, 88 genes had low
expression in both cancer lines. H3K27m3 and DNA hyper-
methylation appeared the commonest epigenetic traits (Figure
S3b). Alone or in combination these events were found in 49–58%
and 54–59% of silenced genes, respectively. Only 6–7% of
silenced genes had isolated H3K9m3 enrichment. Shared patterns
of enrichment for H3K9m3 or H3K27m3, and DNA hyper-
methylation were present in the two cell lines for 8(9%), 34(39%)
and 29(33%) of these 88 genes, respectively.
Multilayered epigenetic gene upregulation
To evaluate epigenetically mediated gene upregulation in
cancer we used the combined dataset (n = 6,809 genes) to identify
those with DNA hypomethylation and/or loss of enrichment for
either histone modification in the cancer cell lines, when compared
to NHU. From these we selected genes with cancer specific
expression (i.e. were silenced in NHU cells, Figure S4). In total, we
found 355 and 373 genes in EJ and RT112, respectively. Of these,
114 genes were silenced in NHU and present in both cancer lines.
DNA hypomethylation appeared the most common epigenetic
trait and was present in for 54–73% of these genes. Reduced
relative H3K27m3 and H3K9m3 enrichment were found in 28–
33% and 4–12% of genes, respectively.
Figure 1. Enrichment for DNA bound to H3K9m3 and H3K27m3 around Transcriptions Start Sites (TSS). Although deep sequencing
reads were mapped throughout the genome, there was enrichment around that varied between H3K9m3 and H3K27m3. The average number of
reads within the 2 kb window surrounding 33,183 transcription start sites (TSS) is shown.
doi:10.1371/journal.pone.0032750.g001
Figure 2. Histone enrichment according to the distance from
Tissue and Cancer specific Differentially Methylated Regions
(DMRs). We calculated the distance from gene TSS (n = 47,746) to the
nearest DMR (C-DMR n= 2,708 and T-DMR n= 16,380) and binned
genes into 30 sets (each dot represents one bin) for which we
calculated average reads within a 10 kb window around the TSS for that
bin. We normalized enrichment reads according to the total number for
that experiment. For C-DMRs, a clear inverse correlation exists between
TSS distance and histone enrichment (Pearson’s correlation coefficients
shown (r)). For T-DMRs the relationship appears more Gaussian in
distribution.
doi:10.1371/journal.pone.0032750.g002
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External validation of genes with carcinogenic aberrant
epigenetic regulation
We combined the epigenetic silencing and upregulation gene
panels to create a list encompassing tumor specific changes within
our cells (n = 202, table S2). To explore this panel we firstly
performed pathway analysis using gene enrichment software [16]
and illustrated using area-proportional Venn diagrams [17].
Whilst the cohort enriched for 5 mC was largest, gene enrichment
analyses suggested that those with associated H3K27m3 were most
biologically active (110 gene clusters, Figure S5, table S3). Pathway
annotation revealed that genes marked with H3K27m3 repre-
sented mitosis/cell division/chromatin assembly (enrichment 2.12,
p = 0.005), regulation of transcription (1.63, p = 0.009), protein
phosphorylation (1.38, p = 0.01), induction of apoptosis and cell
migration/cytoskeleton organization (1.1, p = 0.03). For H3K9m3
there were fewest gene clusters and these represented members of
the response to nutrient/extracellular stimulus (1.1, p = 0.01).
Genes with only 5 mC enrichment were clustered into pathways
dealing with the response to stress/oxidation (1.8, p = 0.002), cell
morphogenesis and movement. Finally, genes with all three
epigenetic marks were concentrated into 5 clusters involving
members of the nucleoside and nucleotide binding, regulation of
gene expression and transcription pathways. Differences also
occurred between genes with cancer associated epigenetic
silencing and upregulation. Whilst the former group was smaller
(88 genes) its members were clustered into 71 pathways, in contrast
to the 47 for the upregulated (114 gene) panel.
To examine the extent of aberrant expression for members of
our epigenetic panel in human UCC we interrogated two
microarray datasets generated using a related Affymetrix platform
(U133A, n= 22,283 probesets (n = 13,703 genes) [18]) and the
largest published with UCC [19]. In the former, we identified 136
gene members from our silenced (58/88) and upregulated (78/
114) panels, and compared their expression in the 9 normal
urothelial and 46 UCC samples. In total, 95/136 (70%) of genes
had their differential expression correctly predicted by our
epigenetic marks (ANOVA p,0.05, Figure S6). Unsupervised
hierarchical clustering separated the samples according to their
phenotype (figure 6), suggesting that our cell line panel reflects
events within primary human cancers. In the second dataset, we
identified 177 members of our panel and correctly predicted the
Figure 3. Histone enrichment and gene expression. We matched
the histone enrichment to mRNA expression for 9,998 genes. All genes
illustrated in these Venn diagrams were expressed, as determined by
Microarray Analysis Suite 5 (see methods). (a). Quantitative analysis
revealed that H3K27m3 enrichment was mostly mutually exclusive to
gene expression. In contrast, up to 52% of TSS with H3K9m3
enrichment had gene expression. (b). Qualitative analysis reveals that
H3K27m3 enrichment is inversely correlated with mRNA expression, in
contrast to H3K9m3. This plot demonstrates average histone enrich-
ment for the 9,998 genes when grouped into 30 bins according to
mRNA expression.
doi:10.1371/journal.pone.0032750.g003
Figure 4. Cytosine methylation and gene expression. (a). Gene
expression was inverse to the density of adjacent probes enriched for
5 mC (data from 10,568 genes (corresponding to 9,799 CpG islands)).
(b). When compared, methylation of 5 mC and H3K9m3 or H3K27m3
appeared usually mutually exclusive. Of the 6809 genes with matching
data, less than 5% shared methylation of 5 mC and either histone
residue.
doi:10.1371/journal.pone.0032750.g004
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expression of 106 (60%). Once again unsupervised hierarchical
clustering using our panel members stratified 10 normal and 85
malignant samples according to phenotype (Figure S7). We
determined expression of our identified epigenetic panel members
in each tumor sub-type (table S4), as low and high grade UCC
arise by distinct tumor pathways. For each tumor phenotype we
saw common and specific events. For example, there were 28
genes specific to invasive tumors when compared to non-muscle
invasive disease and 67 that appeared common to UCC.
Discussion
Here we have produced integrated epigenomic maps for two
UCC cell lines and non-transformed normal urothelial cells. The
latter are cultured expansions taken from disease free patients that
grow as sheets of histologically normal appearing urothelial cells
for 7–8 passages before senescence. Our experimental data reveal
insights into the epigenetic control of gene expression in the
biology of UCC and have specifically identified genes potentially
involved in urothelial carcinogenesis.
At the global level several observations are apparent. Firstly,
H3K9m3 and H3K27m3 are located mostly around gene
transcription start sites [7]. In the UCC lines we observed that
H3K27m3 was less specifically bound to TSS and more evenly
distributed throughout the gene, than for NHU. This may reflect
alterations in H3K27 methylation in UCC, perhaps due to
changes in EZH2 or UTX expression. The EZH2 polycomb
protein specifically methylates H3K27 and is commonly overex-
pressed in UCC [20]. Indeed our gene expression data revealed
EZH2 mRNA was upregulated in both cells when compared to
NHU (data not shown)). UTX is a H3K27m3 demethylase. A
recent report has described a hemizygous deletion (through
mutation) in RT112 cells [21], suggesting deficiency in the
removal of methyl residues in this line. Secondly, our genome wide
sequencing identified few TSS that shared epigenetic marks
between cell lines (1.3–3.7% of mapped TSS). This may reflect
differences in cell phenotype and supports previous observations
defining the diversity of histone modifications [8]. Wang et al.
profiled 37 different histone acetylation and methylation modifi-
cations in CD4+ cells and detected 4,339 different combinations
(of which 3,165 were at only one gene site). Only 1,018 of the
12,541 genes studied had H3K27me3 enrichment (in keeping with
our observations).
Our data detail the associations between H3K9m3, H3K27m3,
CpG islands and DMRs (mostly CpG shores [15]). Of the histone
modifications, H3K9m3 appeared most specific to CpG regions
and was almost exclusively bound to TSS with CpG islands (89–
96%, Figure S1). Consequently enrichment for H3K9m3 was
inversely correlated to distance from CpG shores (figure 2). The
specificity of H3K9m3 for CpG islands supports an interaction
with cytosine methylation [10], although these epigenetic
modifications coexisted infrequently in our cells. Our analysis
suggests that the relationship between 5 mC and H3K9m3 is
strongest in genes with absent or low expression, but does persist
into those with high expression. This lack of specificity suggests
that neither event is sufficient for gene silencing and may explain
the low proportion of genes with both epigenetic marks in our
cells. In contrast, H3K27m3 was less specifically located to TSS
with CpG islands (28–69%) and consequently less correlated to
DMR distance than H3K9m3. Whilst overall there was little
relationship between H3K27m3 and cytosine methylation, a direct
correlation existed in genes with low expression. Whilst this
association may be because both marks are negatively correlated
to gene expression, it could reflect a direct causation (as they affect
distinct TSS). Whilst our methodology has identified associations
between epigenetic marks and gene expression, we did not
examine this cause or direction. Data to examine this relationship
may be obtained from the literature. Schlesinger et al. identified
that genes silenced in cancer are initially associated with
H3K27m3 [22]. This mark is maintained by EZH2, which
recruits DNA methyl transferases and these in turn methylate
previously unmethylated cytosine residues. Rush et al. then
identified that EZH2 specifically recruits DNMT3a, but that this
alone is insufficient for de novo methylation, suggesting a need for
additional events [23]. Support for this order of events could be
Figure 5. Integrated epigenetic gene expression. For each cell line, we have plotted the proportion of genes with enrichment for 5 mC (light
grey area), H3K9m3 or H3K27m3 (light grey area), or both (dark grey area) with respect to gene expression. We calculated this plot for 6809 genes
using sliding windows (each covering 5% of all loci) at 1% intervals. H3K27m3 enrichment is limited to genes with low expression. H3K9m3 and 5 mC
enrichment persist for genes with high expression. Few loci share epigenetic marks.
doi:10.1371/journal.pone.0032750.g005
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found in silenced genes with H3K27m3 but not DNA methylation.
We identified many such examples, as did Kondo et al. [24].
The clearest observations from our data are those regarding the
integrated nature of epigenetic gene regulation in the urothelium.
In malignant cells, at low gene expression around 30% of loci had
associated 5 mC, around 20–30% had associated H3K27m3
enrichment and 5% had both epigenetic marks (figure 5). Genes
with both epigenetic marks included potentially carcinogenic
members such as BCL11A, EHD3 and HAS2 (table S2) and drive
key malignant pathways such as apoptosis avoidance and gene
transcription (table S3). For normal urothelial cells, at low gene
expression a similar proportion of loci had H3K27m3 (30%)
enrichment, but only 15% had associated cytosine methylation.
When the epigenetic marks are analyzed with respect to gene
expression, H3K27m3 appears a specific mark of low gene
expression, 5 mC appears a partial mark of low expression in
malignant cells and H3K9m3 does not appear to be related to
gene expression. In normal cells, 5 mC did not appear to be
strongly correlated with gene expression. These are important
findings, that suggest the dynamic nature of epigenetic modifica-
tions and reveal the importance of H3K27m3 in epigenetic gene
repression. When taken with the observations that EZH2
maintains H3K27m3 and recruits DNA methyl transferases, our
data suggest that the transition from normal to malignant
urothelium is accompanied by a loss of control of both DNA
methylation and H3k27 methylation. When analyzed in detail, we
found alterations of these two epigenetic events occurred in 1/4 of
genes (table S2).
Our analyses identified 202 genes whose epigenetic marks and
differential gene expression suggested an involvement in urothelial
carcinogenesis. For the majority of these genes the epigenetic event
was either H3K27m3 or 5 mC. Gene enrichment pathway
analysis suggested diverse roles for the three epigenetic marks.
For example, genes marked by H3K9m3 were involved in cellular
metabolism and the response to external stimuli. These important
cellular pathways need to remain constant within a cell and not
vary with transformation. In contrast, genes marked with
H3K27m3 appeared carcinogenic in function and were involved
with cell division, chromatin assembly, regulation of transcription,
the induction of apoptosis and cell migration. Genes with only
5 mC enrichment were clustered into pathways dealing with the
response to stress and oxidation, cell morphogenesis and
movement. These pathways represent a mixture of those
important for cell homeostasis and those involved in cancer.
Given our findings (that 5 mC varies with urothelial carcinogen-
esis), one would suspect that the pro-carcinogenic pathways
associated with 5 mC are those contributing to malignant
transformation.
To assess the validity of the genes identified using cell lines, we
examined their expression in 150 normal and malignant urothelial
samples. Our epigenetic panel correctly estimated the expression
of 65% of genes and stratified the tissues according to the presence
and phenotype of cancer. This is important as previous epigenetic
studies using candidate tumor suppressor genes reveal that low-
grade non-invasive cancers differ to high grade and invasive UCC
[11,12]. Our identified gene panel includes many members with
suspected roles in carcinogenic pathways. For example, FEZ1/
LZTS1 (Leucine zipper putative tumour suppressor 1) is a tumour
suppressor gene important for cell cycle control. FEZ1 is located at
chromosome 8p22 in a region deleted in many cancers, including
42% of UCC [25]. Whilst loss of FEZ1 expression has been
identified in UCC [26], the mechanism has remained unclear
[25]. Our data now suggest that epigenetic repression in
association with H3K27m3 is responsible. Gelsolin (GSN) is
involved in actin filament assembly and disassembly. Loss of GSN
expression is detected in UCC and produces changes in
cytoskeletal structure typical for cancer [27]. Our data suggest
H3K27m3 mediated repression is responsible for GSN silencing
and support observations of GSN upregulation when cells are
exposed to histone deacetylase inhibition [28].
Figure 6. Clustering of urothelial samples using genes with
epigenetic alteration in UCC cell lines. Unsupervised hierarchical
clustering using genes filtered to those present within our epigenetic
gene panel stratified urothelial samples according to the presence and
phenotype of cancer. Previously reported microarray data [18] was
filtered for members of our epigenetic panel (blue: upregulated,
orange: down regulated) whose expression was correctly predicted.
Unsupervised average linkage hierarchical clustering was performed on
median centered genes using Cluster 3.0. The selected genes stratify
normal and malignant samples mostly according to phenotype (CIS:
Carcinoma in situ, NMI: Non-muscle invasive UCC). For simplicity only
normal urothelium and primary UCC were used in the analysis.
doi:10.1371/journal.pone.0032750.g006
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One of the most interesting candidates within our panel is the
Cellular Apoptosis Susceptibility/CSE1 chromosome segregation
1-like gene (hCAS/CSE1L). This component of the nuclear
import pathway is frequently upregulated in cancer and located at
20q13 within a region amplified in malignancy [29]. The
carcinogenic role for CSE1L was first detected in apoptosis
avoidance and recently it has been identified as a mediator of p53
function and to associate with chromatin [30]. Specifically, CSE1L
decreased H3K27 methylation at certain p53 target genes to
enable their expression. That we have observed upregulation of
CSE1L in association with reduced H3K27m3 suggests a potential
positive feedback loop whereby increased CSE1L expression
facilitates further CSE1L upregulation.
In conclusion, we have mapped repressive epigenetic events in
malignant and normal urothelial cells. In genes with low
expression we identified associated H3K27m3 and DNA methyl-
ation each in 20–30% of genes and both marks in 5% of genes.
When all genes were analyzed H3K9m3 did not appear to be
associated with expression. DNA methylation was more closely
related to gene expression in cancerous than normal cells.
H3K27m3 was the epigenetic mark most specifically correlated
to gene silencing. We identified a panel of genes with cancer
specific epigenetic mediated aberrant expression including those
with known carcinogenic functions and members potentially
mediating a positive epigenetic feedback loop.
Materials and Methods
Cell lines and nucleic acid extraction
We analyzed bladder cancer cell lines representing non-invasive
and invasive disease (RT112 and EJ/T24, purchased from ATCC)
grown in Dulbecco’s medium with 10% fetal calf serum, and
normal human urothelial (NHU) cells maintained in keratinocyte
serum-free medium containing bovine pituitary extract, epidermal
growth factor (Invitrogen, Paisley, UK) and cholera toxin [31].
NHU cells are non-immortalized and derived from histologically
confirmed normal urothelium obtained from patients without a
history of UCC, using standard methods. From each cell line we
extracted DNA using the QIAquick Purification Kit (QIAGEN,
UK) and RNA using the mirVanaTM kit (Ambion, TX), according
to manufacturer’s specifications (methods detailed elsewhere
[12,32]). Nucleic acid concentrations were measured using a
2100 Bioanalyzer (Agilent, Cheshire, UK).
Chromatin Immunoprecipitation and Solexa sequencing
(ChIP-Seq)
Malignant and normal human urothelial cells were cross-linked
with 1% formaldehyde in PBS for 10 min at room temperature.
Glycine was added to the final concentration of 0.125 M and the
mixture incubated for 5 min to quench unreacted formaldehyde.
Cross-linked cells were washed with PBS, lysed in 250 ml SDS lysis
buffer and sonicated (Bioruptor 200, Diagenode, Lie`ge, Belgium).
Samples were pre-cleared with 15 ml of protein G dynabeads
(Invitrogen) and 50 ml supernatant saved as total input control.
Rotating samples were immunoprecipitated overnight at 4uC with
antibodies against H3K9m3 (Millipore, Watford, UK), H3K27m3
(Millipore) and rabbit IgG as a negative control (Santa Cruz
Biotechnology, CA). The chromatin:antibody complex was
incubated with 20 ml dynabeads protein G for 1 h at 4uC, before
washing and DNA elution. Cross-links were reverted by overnight
incubation with RNAse A at 65uC before DNA purification using
columns (Qiagen, Germany). Immunoprecipitated DNA ends
were repaired using the PNK and Klenow enzyme, adenosine was
added to the 39 end of the fragments and the DNA was ligated
with the adapters. Following ligation, the ChIP DNA was
amplified for 17 cycles and fragments around 200–300 bp isolated
using electrophoresis in an agarose gel. The purified DNA was
used for cluster generation and sequencing analysis using the
Solexa 1 G Genome Analyzer according to manufacturer
protocols (Illumina, CA) as detailed elsewhere [33]. The
sequencing reads (36 bp) were mapped using Bowtie [34] to the
chromosomes of the human genome (NCBI built GRCh37/hg19,
February 2009) allowing up to two mismatches (command line
argument –v 2). Only uniquely mapped reads were used for the
subsequent analysis. If several reads were mapped to the same
position and strand, we counted them as a single read.
Genome wide profiling of DNA methylation
Methylated DNA immunoprecipitation and tiling CpG island
microarrays (Human CpG Island Microarray, Agilent, CA)
(MeDIP-CHIP) were used to determine genome wide distribution
of 5 mC [35]. Briefly, genomic DNA was sheared by sonication to
yield 200–600 bp fragments and incubated with antibodies raised
to either 5 mC (anti-5-methylcytidine, Eurogentec, Hampshire,
UK) or murine IgG (negative control). The antibody-antigen
complex was captured with magnetic beads conjugated to anti-
mouse-IgG (Santa Cruz Biotechnology) and washed, unbound,
non-specific DNA removed, before methylated DNA elution.
Successful enrichment was determined using quantified PCR for
EDNRB (known to be methylated in these cells [14]]). The
immunoprecipitated (Cyanine 5-dUTP) and reference DNA
(Cyanine 3-dUTP) were then labeled (Genomic DNA Enzymatic
Labeling Kit, Agilent), cleaned (Amicon filters, Millipore) and
quantified. Competitive hybridization onto the microarray was
then performed (ChIP-on-Chip Hybridization Kit, Agilent)
according to manufacturer’s instructions in a rotating SureHyb
chamber at 67uC for 40 hours. Washed slides were scanned (High-
Resolution C Scanner, Agilent) and fluorescence obtained using
Feature Extraction software. The microarray contains 244,000
probes that tile through 27,800 CpG features at an average of
100 bp separation. To calculate methylation, we averaged probes
within each CpG region and defined those within the highest and
lowest quintiles (20%) of relative Cy5 fluorescence as hyper or
hypo-methylated, respectively.
mRNA expression
Whole genome mRNA expression was determined by micro-
array (HG-U133 Plus 2.0, Affymetrix, Cal.) as detailed elsewhere
[36]. This platform contains 54,000 probesets, including 33,000 to
known coding genes. Briefly, RNA was prepared using the
Affymetrix protocol (enzymes from Invitrogen) and annealed to an
oligo-d(T) primer with a T7 polymerase binding site. cDNA was
generated using superscript II and E. coli DNA ligase and
polymerase I. The reaction was completed with T4 DNA
polymerase and EDTA. Amplified cDNA was cleaned, biotin-
labeled, fragmented and hybridized to the microarray for 16 hours
at 45uC in a rotating oven at 60 rpm. After washing and staining,
the arrays were scanned (GC3000 scanner) and data processed
using Gene Chip Operating System software. mRNA expression
was determined using Microarray Analysis Suite 5 (Affymetrix)
and defined as expressed (perfect match probeset intensity greater
than mismatch intensity) or absent (mismatch probeset intensity
greater or equal to perfect match intensity).
External validation and statistical analysis
Our analyses identified a panel of genes that appeared to be
important in urothelial carcinogenesis. To evaluate their role in
human UCC, we extracted expression data from Array Express
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(www. generated using related Affymetrix microarrays [18] and
the largest published within this tumor [19]. We analyzed the
selected genes using unsupervised hierarchical clustering with
Cluster 3.0 and TreeView (Eisen lab) as described [12]. For
statistical comparisons we compared epigenetic events using a Chi
squared test for discrete variables and ANOVA for continuous
data. All statistical analyses were two sided and performed in SPSS
(Vsn. 14.0 SPSS Inc, ILL) using p,0.05 for significance.
Data deposition
The raw data from each experiment is deposited on line at
NCBI GEO with accession numbers GSE 31125, GSE 31864,
GSE 31865 and GSE 31866.
Supporting Information
Figure S1 Histone enrichment at individual Transcrip-
tion Start Sites. The number of TSS with shared enrichment for
between each of the three cell lines is shown for (a). all genes and
(b). for genes around CpG islands. As can been seen, H3K9m3
appeared more specific to CpG islands than H3K27m3.
(PDF)
Figure S2 Gene expression and histone enrichment.
Gene expression was an average of more than 10 fold lower in
TSS with H3K27m3 enrichment, compared to those without
enrichment (ANOVA p,0.0001, figure 3b). For H3K9m3 little
difference in gene expression was seen, with respect to enrichment.
(PDF)
Figure S3 Epigenetic gene silencing in bladder cancer.
Venn diagrams represent number of down regulated genes in EJ
and RT112 bladder cancer cell lines, when compared to NHU,
associated with each epigenetic mark.
(PDF)
Figure S4 Epigenetic gene upregulation in bladder
cancer. Venn diagrams represent number of upregulated genes
in EJ and RT112 bladder cancer cell lines, when compared to
NHU, associated with each epigenetic mark.
(PDF)
Figure S5 Functional annotation clustering of genes
with epigenetic marks in EJ cells. Using gene enrichment
pathway analysis we determined clusters of genes for each set
marked by an epigenetic modification. The number of gene
clusters within each part of the diagram is indicated in these area
proportional Venn diagrams.
(PDF)
Figure S6 The expression of genes within our combined
epigenetic panel in an external dataset [18]. The median
expression of 124 genes is shown when stratified according to the
epigenetic traits found in EJ, RT112 and NHU. As shown, genes
with predicted epigenetic upregulation had higher expression than
those with predicted silencing.
(PDF)
Figure S7 Unsupervised hierarchical clustering strati-
fied malignant and normal urothelial samples according
to phenotype. Previously reported microarray data [19] was
filtered for members of our epigenetic panel (blue: upregulated,
orange: downregulated) whose expression was correctly predicted.
Unsupervised average linkage hierarchical clustering was per-
formed on median centered genes using Cluster 3.0. The selected
genes stratify normal and malignant samples mostly according to
phenotype (Yellow: Normal, Blue: Non-muscle invasive and Red:
Invasive/metastatic). For simplicity we evaluated only normal
urothelium from control patients without cancer, and tumors
characteristic of the low grade and invasive pathways.
(PDF)
Table S1 Reads per experiment obtained from mas-
sively parallel sequencing.
(PDF)
Table S2 Details of the combined epigenetic gene panel
stratified for associated events and mRNA expression.
Below each column is the proportion of total events (as a
percentage).
(PDF)
Table S3 Gene ontology analysis for each epigenetic
mark. The table reveals the GO details for all identified pathways
associated with each event.
(PDF)
Table S4 Phenotype specific gene expression in the
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